Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
$4.81
-5.1%
$5.71
$4.29
$14.44
$4.28M1.44328,001 shs916 shs
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
$0.25
$0.82
$0.22
$2.79
$2.76M0.98277,993 shs18,144 shs
Nuwellis, Inc. stock logo
NUWE
Nuwellis
$0.33
-1.2%
$0.46
$0.24
$5.73
$2.24M0.17896,398 shs5.17 million shs
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
$0.00
$0.00
$0.00
$0.11
$3K0.082,663 shs18 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
-4.37%-15.90%-15.05%-29.31%-51.17%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
+1.30%-4.50%-73.10%-74.98%-86.10%
Nuwellis, Inc. stock logo
NUWE
Nuwellis
+29.96%-9.29%-23.57%-42.41%-92.20%
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
0.00%0.00%+50.00%+50.00%-99.44%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
1.2579 of 5 stars
3.54.00.00.00.00.00.6
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Nuwellis, Inc. stock logo
NUWE
Nuwellis
N/AN/AN/AN/AN/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
3.00
Buy$54.501,033.06% Upside
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A
Nuwellis, Inc. stock logo
NUWE
Nuwellis
2.00
HoldN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/A

Current Analyst Ratings

Latest NUWE, VIVE, HSDT, and NDRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/5/2024
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
$640K6.69N/AN/A$3.32 per share1.45
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A$0.67 per shareN/A
Nuwellis, Inc. stock logo
NUWE
Nuwellis
$8.86M0.25N/AN/A$0.53 per share0.62
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
$6.43M0.00N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
-$8.85M-$14.46N/AN/AN/A-1,374.22%-221.11%-86.23%5/9/2024 (Estimated)
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-$10.06M-$1.93N/AN/AN/A-197.36%-144.22%5/20/2024 (Estimated)
Nuwellis, Inc. stock logo
NUWE
Nuwellis
-$20.21M-$13.46N/AN/AN/A-227.99%-218.79%-140.88%5/14/2024 (Estimated)
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
-$22.03MN/A0.00N/AN/AN/AN/AN/A

Latest NUWE, VIVE, HSDT, and NDRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
-$4.05-$1.47+$2.58-$1.47$0.18 million$0.13 million
3/28/2024Q4 2023
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A-$0.17-$0.17-$0.17N/AN/A
3/5/202412/31/2023
Nuwellis, Inc. stock logo
NUWE
Nuwellis
-$1.39-$2.24-$0.85-$2.24N/A$2.55 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
N/AN/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/A
Nuwellis, Inc. stock logo
NUWE
Nuwellis
N/AN/AN/AN/AN/A
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
N/A
3.96
3.72
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A
6.26
3.36
Nuwellis, Inc. stock logo
NUWE
Nuwellis
N/A
2.59
1.96
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
18.63%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
1.19%
Nuwellis, Inc. stock logo
NUWE
Nuwellis
3.13%
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
N/A

Insider Ownership

CompanyInsider Ownership
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
7.30%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
4.80%
Nuwellis, Inc. stock logo
NUWE
Nuwellis
0.88%
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
5.73%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Helius Medical Technologies, Inc. stock logo
HSDT
Helius Medical Technologies
26890,000822,000Not Optionable
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
2111.04 million10.51 millionNot Optionable
Nuwellis, Inc. stock logo
NUWE
Nuwellis
596.80 million6.74 millionNot Optionable
Viveve Medical, Inc. stock logo
VIVE
Viveve Medical
4710.72 million10.11 millionNot Optionable

NUWE, VIVE, HSDT, and NDRA Headlines

SourceHeadline
5-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 20285-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 2028
finance.yahoo.com - April 17 at 6:28 PM
InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTLInMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
finance.yahoo.com - April 15 at 7:58 AM
Viveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, PredictionsViveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 23 at 10:31 AM
The Best Medical Billing Services of 2024The Best Medical Billing Services of 2024
business.com - January 19 at 10:31 PM
VIVE Viveve Medical, Inc.VIVE Viveve Medical, Inc.
seekingalpha.com - July 29 at 9:53 AM
InMode Expands Womens Health and Wellness Market Footprint through Acquisition of Viveve PatentsInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve Patents
finance.yahoo.com - July 25 at 9:01 AM
VIVE - Viveve Medical, Inc.VIVE - Viveve Medical, Inc.
uk.finance.yahoo.com - June 14 at 7:59 PM
Viveve Medical, Inc. (VIVE)Viveve Medical, Inc. (VIVE)
finance.yahoo.com - February 24 at 8:19 AM
Viveve Medical announces study result from PURSUIT clinical trial to treat female stress urinary incontinenceViveve Medical announces study result from PURSUIT clinical trial to treat female stress urinary incontinence
pharmabiz.com - January 20 at 9:26 AM
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesdays Mid-Day SessionWhy Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
msn.com - January 17 at 3:40 PM
Viveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceViveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
finanznachrichten.de - January 17 at 10:39 AM
Viveve crashes ~60% as company decides to delist, explore sale after trial failsViveve crashes ~60% as company decides to delist, explore sale after trial fails
seekingalpha.com - January 17 at 10:39 AM
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceViveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
finance.yahoo.com - January 17 at 10:39 AM
Viveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence TrialViveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence Trial
finance.yahoo.com - January 17 at 10:39 AM
Why Is Viveve Medical (VIVE) Stock Down 69% Today?Why Is Viveve Medical (VIVE) Stock Down 69% Today?
investorplace.com - January 17 at 10:03 AM
Viveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call TranscriptViveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call Transcript
insidermonkey.com - December 29 at 9:56 AM
Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits ConcludedViveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded
finance.yahoo.com - December 15 at 10:21 AM
Viveve gets US patent for treating female stress urinary incontinenceViveve gets US patent for treating female stress urinary incontinence
pharmabiz.com - December 3 at 7:46 AM
Viveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceViveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
finanznachrichten.de - December 1 at 12:46 PM
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceViveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
finance.yahoo.com - December 1 at 12:46 PM
Viveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagViveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - November 13 at 7:01 PM
InvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate UpdateInvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate Update
markets.buffalonews.com - November 12 at 7:52 AM
Viveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateViveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
finanznachrichten.de - November 10 at 4:16 PM
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateViveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - November 10 at 4:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Helius Medical Technologies logo

Helius Medical Technologies

NASDAQ:HSDT
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
ENDRA Life Sciences logo

ENDRA Life Sciences

NASDAQ:NDRA
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Nuwellis logo

Nuwellis

NASDAQ:NUWE
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Viveve Medical logo

Viveve Medical

NASDAQ:VIVE
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.